These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25862875)

  • 21. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.
    Chevli KK; Duff M; Walter P; Yu C; Capuder B; Elshafei A; Malczewski S; Kattan MW; Jones JS
    J Urol; 2014 Jun; 191(6):1743-8. PubMed ID: 24333241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.
    Mabjeesh NJ; Lidawi G; Chen J; German L; Matzkin H
    BJU Int; 2012 Oct; 110(7):993-7. PubMed ID: 22394668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.
    Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
    Jpn J Clin Oncol; 2004 Oct; 34(10):602-7. PubMed ID: 15591458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    N Engl J Med; 2003 Jul; 349(4):335-42. PubMed ID: 12878740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test.
    Optenberg SA; Clark JY; Brawer MK; Thompson IM; Stein CR; Friedrichs P
    Urology; 1997 Nov; 50(5):665-72. PubMed ID: 9372872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
    Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
    Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Moreira DM; Gerber L; Thomas JA; Bañez LL; McKeever MG; Freedland SJ
    Int J Urol; 2012 Aug; 19(8):741-7. PubMed ID: 22487442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening: should more biopsies be taken in larger prostates?
    van Leeuwen P; van den Bergh R; Wolters T; Schröder F; Roobol M
    BJU Int; 2009 Oct; 104(7):919-24. PubMed ID: 19466943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
    Abdel-Khalek M; El-Baz M; Ibrahiem el-H
    BJU Int; 2004 Sep; 94(4):528-33. PubMed ID: 15329106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unilateral prostate cancer cannot be accurately predicted in low-risk patients.
    Isbarn H; Karakiewicz PI; Vogel S; Jeldres C; Lughezzani G; Briganti A; Montorsi F; Perrotte P; Ahyai SA; Budäus L; Eichelberg C; Heuer R; Köllermann J; Sauter G; Schlomm T; Steuber T; Haese A; Zacharias M; Fisch M; Heinzer H; Huland H; Chun FK; Graefen M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):784-7. PubMed ID: 19864083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
    Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
    J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy.
    Cormio L; Lucarelli G; Selvaggio O; Di Fino G; Mancini V; Massenio P; Troiano F; Sanguedolce F; Bufo P; Carrieri G
    Medicine (Baltimore); 2016 Feb; 95(7):e2551. PubMed ID: 26886598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence and severity of lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy.
    Cicione A; Cormio L; Cantiello F; Palumbo IM; DE Nunzio C; Lima E; Ucciero G; Carrieri G; Damiano R
    Minerva Urol Nefrol; 2017 Oct; 69(5):486-492. PubMed ID: 28124868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.